As head of the section of Bioanalytical Chemistry, I oversee a talented and diverse team of experts responsible for the development and application of novel analytical methodology for global profiling and targeted analysis of small molecules, peptides, lipids and proteins. Our principal application space includes human biofluids and tissue extracts as well as the animal models and cell cultures needed to explore disease mechanisms in greater depth. Our favoured technology platforms include nuclear magnetic resonance (NMR), liquid chromatography mass spectrometry (LC-MS) and LC-tandem mass spectrometry (LC-MS/MS). We are most active in the areas of:
- Analytical method development
- Technology development and refinement
- Data extraction and pre-processing workflows
- Data quality control and monitoring
- Metabolite assignment and identification including structure elucidation
Together we work closely with clinicians, epidemiologists, and basic science researchers at Imperial to provide innovative and reliable bioanalytical solutions for metabolomics, lipidomics, and proteomics.
As the Chief Operations Officer for the National Phenome Centre (NPC), I am responsible for operational management and delivery of a wide portfolio of research collaborations. Within the NPC, our focus is split between meeting the needs of high precision analysis demanded by large sample cohorts from molecular epidemiology studies, and those of studies involving smaller clinically derived cohorts analysed using both established and developing technologies.
et al., 2023, Small intestinal permeability and metabolomic profiles in feces and plasma associate with clinical response in patients with active psoriatic arthritis participating in a fecal microbiota transplantation trial: exploratory findings from the FLORA trial, Acr Open Rheumatology, ISSN:2578-5745
et al., 2023, The postprandial secretion of peptide YY<sub>1-36</sub> and <sub>3-36</sub> in obesity is differentially increased after gastric bypass versus sleeve gastrectomy, Clinical Endocrinology, Vol:99, ISSN:0300-0664, Pages:272-284
et al., 2023, Commentary on "The road to reliable peptide assays is paved with good guidelines", Clinical Endocrinology, Vol:98, ISSN:0300-0664, Pages:763-765
et al., 2023, Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer, Microbiome, Vol:11, ISSN:2049-2618, Pages:1-14
et al., 2023, A proposed framework to evaluate the quality and reliability of targeted metabolomics assays from the UK Consortium on Metabolic Phenotyping (MAP/UK), Nature Protocols, Vol:18, ISSN:1754-2189, Pages:1017-1027